Biotech Archives - Page 703 of 795

2 minute read

Syros Shares Soar As FDA Grants Orphan Drug Status To Pancreatic Cancer Candidate

September 13, 4:23 PM

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Syros Pharmaceuticals (NASDAQ: SYRS) lead candidate SY-5609 for the treatment of pancreatic cancer.

SYRS

1 minute read

Palisade Bio Granted U.S. Patent Titled ‘Administration of serine protease inhibitors to the stomach’

By Benzinga Newsdesk

September 13, 4:15 PM

https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11439611.PN.&OS=PN/1143961

PALI

2 minute read

Syros Receives FDA Orphan Drug Designation For SY-5609 For The Treatment Of Pancreatic Cancer

By Benzinga Newsdesk

September 13, 4:01 PM

Syros Pharmaceuticals, Inc. (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug

SYRS

1 minute read

Biden Administration Pushes ‘Cancer Moonshot’ Initiative: Report

By Vandana Singh

September 13, 2:36 PM

President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it." The President underscored his goal to cut the cancer death rate in the U.S. by at least 50% over the next 25 years.

ABBV

1 minute read

A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says

By Vandana Singh

September 13, 2:01 PM

Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati

NVS

1 minute read

Vaxxinity Starts Dosing In Phase 1 Migraine Vaccine Trial

By Vandana Singh

September 13, 11:58 AM

Vaxxinity Inc (NASDAQ:VAXX) announced that the first subjects had been dosed in the Phase 1 clinical trial of UB-313, a vaccine…

VAXX

1 minute read

Merck Secures Canadian Regulatory Nod For KEYTRUDA In Skin Cancer After Resection

By Ragothaman Srinivasan

September 13, 11:19 AM

Health Canada has granted approval for Merck’s (NYSE: MRK) KEYTRUDA (pembrolizumab) for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following complete resection.

MRK

1 minute read

“Synthetic Biologics has received a Notice of Allowance for its US patent application 17/314,583 titled ‘E. COLI-BASED PRODUCTION OF BETA-LACTAMASE (FOR MICROBIOME-PROTECTING THERAPY)’. Recent reverse split.” – PatentGrants

By Benzinga Newsdesk

September 13, 10:54 AM

https://twitter.com/PatentGrants/status/1569700636505296901 https://patentcenter.uspto.gov/#!/applications/17314583/ifw/docs

SYN

1 minute read

FDA Clears Akouos’ Gene Therapy Trial For Genetic Form Of Hearing Loss

By Vandana Singh

September 13, 9:53 AM

The FDA has signed off Akouos Inc’s (NASDAQ:AKUS) Investigational New Drug application to initiate a Phase 1/2 trial of AK-OTOF, gene…

AKUS

1 minute read

aTyr Pharma Gets FDA Fast Track Status For Systemic Sclerosis Candidate

By Ragothaman Srinivasan

September 13, 9:18 AM

The U.S. Food and Drug Administration (FDA) has granted Fast Track designation for aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod, for the treatment of systemic sclerosis (SSc)-associated, interstitial lung disease (ILD).

LIFE